High-resolution Magnetic Resonance Imaging of Intracranial Atherosclerotic Plaques in Ischemic Stroke

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorGeneral Hospital of Shenyang Military Region

About this trial

Intracranial atherosclerotic disease is the most common cause of ischemic stroke in Asia, also in China. Currently, despite vascular recanalization therapy, statins are one of the main drug choices for treating atherosclerotic plaque. High resolution magnetic resonance imaging (HRMRI) can accurately assess the status of intracranial and extracranial arterial plaque, and has high consistency with histopathology. Thus, HRMRI technology has been widely used to monitor the efficacy of drug treatment for atherosclerotic plaque in clinical trials or practice.

As a non-invasive technique, HRMRI make it possible to assess the morphologic characteristics of vascular wall and plaque composition of intracranial artery in vivo. It can quantitative analysis including components such as lipid-rich necrotic core, fiber cap thickness, intra-plaque hemorrhage, calcification, etc. Therefore, it is crucial for evaluating the etiology of ischemic stroke and developing secondary prevention strategies.

At present, there is a lack of large-scale and prospective study to evaluate the etiology of ischemic stroke including cryptogenic stroke based on HRMRI. In this context, this study aims to establish a multi center HRMRI database of intracranial arteries among Chinese patients with ischemic stroke.

Eligibility criteria

Qualifiers

1. Patient age ≥40 years

2. Time of stroke onset: within 2 week

3. Baseline NIHSS score ≤16

4. Ischemic stroke confirmed by head CT or MRI

Disqualifiers

1. Intracranial hemorrhage found by head CT

2. Had a contraindication to MRI,or could not complete required MRI sequences

3. Intracranial tumor, arteriovenous malformation, or aneurysm

4. Comorbidity with any serious diseases and life expectancy is less than one year

Trial design

Treatments tested in this trial

  • Registration

Treatment groups

No treatment groups listed